Diffuse Large B-Cell Lymphoma, Not Otherwise Specified Clinical Trials

8 recruiting

Diffuse Large B-Cell Lymphoma, Not Otherwise Specified Trials at a Glance

14 actively recruiting trials for diffuse large b-cell lymphoma, not otherwise specified are listed on ClinicalTrialsFinder across 6 cities in 3 countries. The largest study group is Phase 2 with 10 trials, with the heaviest enrollment activity in Seattle, Oklahoma City, and New York. Lead sponsors running diffuse large b-cell lymphoma, not otherwise specified studies include National Cancer Institute (NCI), University of Washington, and David Bond, MD.

Browse diffuse large b-cell lymphoma, not otherwise specified trials by phase

Treatments under study

About Diffuse Large B-Cell Lymphoma, Not Otherwise Specified Clinical Trials

Looking for clinical trials for Diffuse Large B-Cell Lymphoma, Not Otherwise Specified? There are currently 8 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Diffuse Large B-Cell Lymphoma, Not Otherwise Specified trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Diffuse Large B-Cell Lymphoma, Not Otherwise Specified clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 114 of 14 trials

Recruiting
Phase 2

Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsRefractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsRecurrent Diffuse Large B-Cell Lymphoma+12 more
National Cancer Institute (NCI)120 enrolled82 locationsNCT06649812
Recruiting
Phase 1

Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
National Cancer Institute (NCI)30 enrolled8 locationsNCT06015880
Recruiting
Phase 2

Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Recurrent Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell LymphomaRefractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell LymphomaRecurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified+5 more
City of Hope Medical Center43 enrolled3 locationsNCT07365306
Recruiting
Phase 2

Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T

Recurrent Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-Cell LymphomaRecurrent High Grade B-Cell Lymphoma+9 more
University of Washington27 enrolled1 locationNCT06784726
Recruiting
Phase 2

A Study of WZTL-002 CAR T-cells for Adults With Relapsed Large B-cell Lymphoma

Large B-cell LymphomaPrimary Mediastinal Large B-cell Lymphoma (PMBCL)Diffuse Large B-Cell Lymphoma, Not Otherwise Specified+1 more
Malaghan Institute of Medical Research60 enrolled3 locationsNCT06486051
Recruiting
Phase 1

Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma

High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 RearrangementsHigh Grade B-Cell Lymphoma, Not Otherwise SpecifiedDiffuse Large B-Cell Lymphoma, Not Otherwise Specified+3 more
University of Washington56 enrolled1 locationNCT04231877
Recruiting
Phase 1

P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies

High-grade B-cell LymphomaDLBCL - Diffuse Large B Cell LymphomaPrimary Mediastinal Large B-cell Lymphoma (PMBCL)+7 more
Poseida Therapeutics, Inc.120 enrolled17 locationsNCT06014762
Recruiting
Phase 2

Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy

Recurrent Grade 3b Follicular LymphomaRefractory Grade 3b Follicular LymphomaRecurrent Transformed Non-Hodgkin Lymphoma+28 more
Mayo Clinic41 enrolled7 locationsNCT06834373
Recruiting
Not Applicable

ctDNA-guided Therapy Optimization in Newly Diagnosed DLBCL

Diffuse Large B Cell LymphomaHigh-grade B-cell LymphomaLymphoma+2 more
Hua-Jay J Cherng, MD40 enrolled1 locationNCT06693830
Recruiting
Phase 1Phase 2

ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma

Recurrent Diffuse Large B-Cell LymphomaRecurrent Grade 3b Follicular LymphomaRecurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Fred Hutchinson Cancer Center33 enrolled1 locationNCT07098364
Recruiting
Phase 2

Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma

Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsRefractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsRecurrent Grade 3b Follicular Lymphoma+19 more
David Bond, MD37 enrolled1 locationNCT05821088
Recruiting
Phase 2

Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma

Recurrent Diffuse Large B-Cell LymphomaRecurrent Nodal Marginal Zone LymphomaRefractory Diffuse Large B-Cell Lymphoma+11 more
Joseph Tuscano25 enrolled1 locationNCT06905509
Recruiting
Phase 1Phase 2

A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies

Chronic Lymphocytic Leukemia (CLL)High Grade B-Cell Lymphoma, Not Otherwise SpecifiedMultiple Myeloma (MM)+3 more
IDP Discovery Pharma S.L.37 enrolled11 locationsNCT05908409
Recruiting
Phase 2

Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy

Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Academic and Community Cancer Research United120 enrolled6 locationsNCT06238648